{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:36:27Z","timestamp":1787956587777,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007920","name":"university of massachusetts medical school","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001299","name":"prevent cancer foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>B-cell proliferative disorders, such as post-transplant lymphoproliferative disease (PTLD), are increased among persons afflicted by T-cell compromise.\u00a0Most are Epstein\u2013Barr virus (EBV)\u2009+\u2009and can first present with a focal lesion. Direct introduction of oncolytic viruses into localized tumors provides theoretical advantages over chemotherapy, immunotherapy and radiation therapy by reducing systemic toxicity. Despite extensive study as a vehicle for gene therapy, adeno-associated viruses (AAV) have rarely been applied to human cancer research due to technical and theoretical obstacles. Moreover, human B-cells have historically been described as resistant to AAV infection. Nonetheless, advances using different recombinant (r)AAV serotypes with unique tropisms to deliver cytotoxic therapy suggested a localized anti-tumor approach was feasible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>As a prelude to the development of a therapeutic vehicle, the ability of fifteen distinct EGFP-bearing rAAV serotypes to transduce human B-cells, including primary, immortalized, and B-cell tumor lines\u2009\u00b1\u2009EBV was assessed by confocal microscopy, flow cytometry and subsequently cell viability assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Rank order analysis revealed augmented transduction by rAAV6.2 and closely related virions. EBV infection of EBV-negative B-cell tumor lines and EBV immortalization of primary B-cells increased susceptibility to rAAV6.2 transduction. As a proof of concept, transduction by rAAV6.2 encoding herpes simplex virus type 1 (HSV1)-thymidine kinase (TK) eliminated TK-negative rhabdomyosarcoma cells and diminished viability of transduced B-cell lines upon incubation with ganciclovir.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>rAAV serotypes differentially transduce human B-cell lines reversing the dogma that human B-cells are refractory to AAV infection. EBV\u2009+\u2009B-cells display increased susceptibility to rAAV6.2 infection, uncovering a new method for improved nucleic acid transfer into transfection-resistant B-cell lines. The introduction of a functional suicide gene into the rAAV6.2 genome identifies a candidate vector for the development of rAAV-based oncolytic therapy targeting focal EBV-bearing B-lymphoproliferative disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-021-01695-w","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:03:12Z","timestamp":1637236992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein\u2013Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV\u2009+\u2009lymphoproliferative disorders"],"prefix":"10.1186","volume":"18","author":[{"given":"Elham","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Ravanshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep S.","family":"Jubbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Guangping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Ziyaeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-1731","authenticated-orcid":false,"given":"Joyce","family":"Fingeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"1695_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41390-019-0591-5","volume":"87","author":"HH Balfour","year":"2020","unstructured":"Balfour HH, Schmeling DO, Grimm-Geris JM. The promise of a prophylactic Epstein\u2013Barr virus vaccine. Pediatr Res. 2020;87:345\u201352.","journal-title":"Pediatr Res"},{"key":"1695_CR2","doi-asserted-by":"publisher","first-page":"10427","DOI":"10.1128\/JVI.76.20.10427-10436.2002","volume":"76","author":"KL Carter","year":"2002","unstructured":"Carter KL, Cahir-McFarland E, Kieff E. Epstein\u2013Barr virus-induced changes in B-lymphocyte gene expression. J Virol. 2002;76:10427\u201336.","journal-title":"J Virol"},{"key":"1695_CR3","first-page":"151","volume":"391","author":"O Cen","year":"2015","unstructured":"Cen O, Longnecker R. Latent Membrane Protein 2 (LMP2). Curr Top Microbiol Immunol. 2015;391:151\u201380.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1695_CR4","volume-title":"Richman clinical virology","author":"J Fingeroth","year":"2017","unstructured":"Fingeroth J. Epstein\u2013Barr Virus. In: Richman DD, Whitley RJ, editors. Richman clinical virology. 4th ed. Washington, DC: American Society for Microbiology; 2017.","edition":"4"},{"key":"1695_CR5","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"GP Gao","year":"2002","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99:11854\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1695_CR6","doi-asserted-by":"publisher","first-page":"14647","DOI":"10.1128\/JVI.79.23.14647-14659.2005","volume":"79","author":"MB Gill","year":"2005","unstructured":"Gill MB, Murphy JE, Fingeroth JD. Functional divergence of Kaposi\u2019s sarcoma-associated herpesvirus and related gamma-2 herpesvirus thymidine kinases: novel cytoplasmic phosphoproteins that alter cellular morphology and disrupt adhesion. J Virol. 2005;79:14647\u201359.","journal-title":"J Virol"},{"issue":"Suppl 3","key":"1695_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ajt.12004","volume":"13","author":"M Green","year":"2013","unstructured":"Green M, Michaels MG. Epstein\u2013Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg. 2013;13(Suppl 3):41\u201354.","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"1695_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discovery. 2019;18:689\u2013706.","journal-title":"Nat Rev Drug Discovery"},{"key":"1695_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","volume":"26","author":"KL Hung","year":"2018","unstructured":"Hung KL, Meitlis I, Hale M, Chen CY, Singh S, Jackson SW, Miao CH, Khan IF, Rawlings DJ, James RG. Engineering protein-secreting plasma cells by homology-directed repair in primary human b cells. Mol Ther J Am Soc Gene Ther. 2018;26:456\u201367.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1695_CR10","first-page":"119","volume":"391","author":"A Kieser","year":"2015","unstructured":"Kieser A, Sterz KR. The Latent Membrane Protein 1 (LMP1). Curr Top Microbiol Immunol. 2015;391:119\u201349.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1695_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.V85.5.1289.bloodjournal8551289","volume":"85","author":"I Kuhn-Hallek","year":"1995","unstructured":"Kuhn-Hallek I, Sage DR, Stein L, Groelle H, Fingeroth JD. Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein\u2013Barr virus-bearing B cells. Blood. 1995;85:1289\u201399.","journal-title":"Blood"},{"key":"1695_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/cgt.2011.51","volume":"18","author":"B Ladd","year":"2011","unstructured":"Ladd B, O\u2019Konek JJ, Ostruszka LJ, Shewach DS. Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK\/ganciclovir. Cancer Gene Ther. 2011;18:751\u20139.","journal-title":"Cancer Gene Ther"},{"key":"1695_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/(SICI)1099-1654(200003\/04)10:2<83::AID-RMV262>3.0.CO;2-T","volume":"10","author":"ER Leight","year":"2000","unstructured":"Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein\u2013Barr virus. Rev Med Virol. 2000;10:83\u2013100.","journal-title":"Rev Med Virol"},{"key":"1695_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.cgt.7700876","volume":"12","author":"C Li","year":"2005","unstructured":"Li C, Bowles DE, van Dyke T, Samulski RJ. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005;12:913\u201325.","journal-title":"Cancer Gene Ther"},{"key":"1695_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/mt.2008.261","volume":"17","author":"MP Limberis","year":"2009","unstructured":"Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther J Am Soc Gene Ther. 2009;17:294\u2013301.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1695_CR16","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","volume":"16","author":"DM McCarty","year":"2008","unstructured":"McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther J Am Soc Gene Ther. 2008;16:1648\u201356.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1695_CR17","unstructured":"Rohr U, Kronenwett R, Haas R (1999) Transduction efficiencies of primary normal and malignant cells using a recombinant AAV-2 vector depend on cell type and cell cycle, Blood. AMER SOC HEMATOLOGY 1200 19TH ST, NW, STE 300, WASHINGTON, DC 20036-2422 USA, pp 181A\u2013181A."},{"key":"1695_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1089\/hum.2019.127","volume":"30","author":"JD Rubin","year":"2019","unstructured":"Rubin JD, Nguyen TV, Allen KL, Ayasoufi K, Barry MA. Comparison of gene delivery to the kidney by adenovirus, adeno-associated virus, and lentiviral vectors after intravenous and direct kidney injections. Hum Gene Ther. 2019;30:1559\u201371.","journal-title":"Hum Gene Ther"},{"key":"1695_CR19","first-page":"669","volume":"59","author":"LZ Rubsam","year":"1999","unstructured":"Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M, Shewach DS. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Can Res. 1999;59:669\u201375.","journal-title":"Can Res"},{"key":"1695_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, Finn EE, Nguyen QG, Blankinship MJ, Meuse L, Chamberlain JS, Hauschka SD. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther J Am Soc Gene Ther. 2007;15:320\u20139.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1695_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","volume":"240","author":"JL Santiago-Ortiz","year":"2016","unstructured":"Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Rel Off J Control Release Soc. 2016;240:287\u2013301.","journal-title":"J Control Rel Off J Control Release Soc"},{"key":"1695_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15257771003741091","volume":"29","author":"T Skovgaard","year":"2010","unstructured":"Skovgaard T, Rasmussen LJ, Munch-Petersen B. Thymidine kinase 1 deficient cells show increased survival rate after UV-induced DNA damage. Nucleosides, Nucleotides Nucleic Acids. 2010;29:347\u201351.","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"key":"1695_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2018.04.005","volume":"9","author":"LP van Lieshout","year":"2018","unstructured":"van Lieshout LP, Domm JM, Rindler TN, Frost KL, Sorensen DL, Medina SJ, Booth SA, Bridges JP, Wootton SK. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice. Mol Ther Methods Clin Dev. 2018;9:323\u20139.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1695_CR24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/gt.2009.101","volume":"16","author":"LH Vandenberghe","year":"2009","unstructured":"Vandenberghe LH, Breous E, Nam HJ, Gao G, Xiao R, Sandhu A, Johnston J, Debyser Z, Agbandje-McKenna M, Wilson JM. Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther. 2009;16:1416\u201328.","journal-title":"Gene Ther"},{"key":"1695_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"1695_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/10428190310001638896","volume":"45","author":"CM Wendtner","year":"2004","unstructured":"Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma. 2004;45:897\u2013904.","journal-title":"Leuk Lymphoma"},{"key":"1695_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/104303401300042500","volume":"12","author":"L Xu","year":"2001","unstructured":"Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther. 2001;12:563\u201373.","journal-title":"Hum Gene Ther"},{"key":"1695_CR28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R, Xu Z, Gao G. Several rAAV vectors efficiently cross the blood\u2013brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther J Am Soc Gene Ther. 2011;19:1440\u20138.","journal-title":"Mol Ther J Am Soc Gene Ther"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-021-01695-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:06:45Z","timestamp":1637237205000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-021-01695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1186\/s12985-021-01695-w","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Normal discarded and unidentified human splenic B-lymphocytes that were consented for research were obtained from New England Organ Bank. The tissues were obtained in accordance with the policies of the Institutional Review Board (IRB) of the New England Organ Bank and the University of Massachusetts Medical Center under an IRB-approved protocol (H00004283, Dr. Fingeroth). The work performed with the NEOB discarded and deidentified human cells was deemed not human research by the UMMS IRB and the NEOB approved this distinction.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, this manuscript does not contain any identifiable patient information that requires consent. All human cell lines were either obtained from the NEOB as deidentified and discarded cells or from commercial vendors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}